Videos

The chief scientific officer of Precision for Medicine discussed unique difficulties of designing clinical trials for PD gene therapy candidates.

The professor from Cedars Sinai discussed further research being conducted in the field after lifileucel’s approval.

The head of research at Mass General Brigham’s Cell and Gene Therapy Institute discussed work the center is engaged in with cell and gene therapy.

The chief medical officer of Encoded Therapeutics overviews the company’s timeline and strategy for its gene regulation program for Dravet syndrome.

The clinical professor of neurology and pediatrics at Keck School of Medicine of USC discussed her learning experience administering gene therapies for the first time.

The Senior Director and Head of Technology Development at Epic Bio discussed potential applications of the new technology.

The medical director of clinical development at AskBio discussed the progress of an early clinical trial of AB-1002.

The deputy director, Division of Rare Diseases Research Innovation, NCATS, NIH, discussed areas that the agency is targeting.

The scientist from Krembil Research Institute shared takeaways from the session she chaired.

The pediatric neurologist at Nemours Children’s Health discussed next steps in the field to fully enable the benefits of gene therapy.

The lead scientist at Percheron Therapeutics discussed research on antisense oligonucleotide therapies in mouse models of DMD.

The cofounder and chief scientific officer at Earli discussed the company’s unique approach to cancer diagnosis.

The director of the Mount Sinai Fuster Heart Hospital discussed how artificial intelligence complements data-driven research.

The McCaw Endowed Chair of Muscular Dystrophy at University of Washington discussed the role the ASGCT plays in the field.

The chief of cardiology at Weill Cornell Medical College discussed the center’s increased focus on genetic research.

The Don and Marilyn Anderson Professor of Oncology at University of Wisconsin – Madison shared highlights from the discussion.

The chief product officer at Mission Bio discussed the company’s Genome Editing Solution.

The professor in the Department of Lymphoma/Myeloma at MD Anderson Cancer Center discussed the advantages the newly approved CAR-T has for older, frailer patients.

The associate professor of clinical pediatrics at Cincinnati Children's discussed further investigations into novel therapies and new research.

The professor of pediatric hematology/oncology at CS Mott Children’s Hospital discussed a sub analysis of the HOPE-B trial.

The assistant professor at Moffit Cancer Center discussed the subgroup analysis she presented at ASCO’s 2024 Annual Meeting.

The Chief Medical Officer of Addimmune discussed the unmet need with HIV and research the company is conducting.

The associate professor of medicine at University of Colorado discussed updated follow-up data from the phase 3 TRANSFORM trial presented at the 2024 ASCO meeting.

The professor from Cedars Sinai also discussed additional investigations evaluating lifileucel for other advanced subtypes of melanoma.

The McCaw Endowed Chair of Muscular Dystrophy at University of Washington shared his outlook on the trajectory of research in the field.

The assistant professor at Mayo Clinic School of Medicine shared her outlook and predictions on research with T-cell lymphomas.

The chief product officer at Mission Bio discussed the company’s Genome Editing Solution.

The deputy director, clinical research, San Raffaele Telethon Institute for gene therapy, discussed long-term follow-up data of up to 12 years.